Recently AmoyDx ROS1 gene fusion detection kit (fluorescence PCR method) was approved by Taiwan Food and Drug Administration（TFDA).

Prior to this, the AmoyDx ROS1 Gene Fusion Detection Kit has been approved by China NMPA, Japan PMDA and Korea MFDS and CE certified in the European Union. The product is simple, convenient, accurate, and applicable to a wide range of sample types. It is an irreplaceable companion diagnostic reagent for clinical treatment of lung cancer patients, providing the highest scientific standard for clinical diagnosis. With the approval by TFDA in Taiwan, AmoyDx ROS1 kit will benefit more lung cancer patients from precision medicine therapy.The approval of this product in Taiwan will further enhance the competitiveness of the company in markets other than mainland China and will have a positive impact on the company's future development.

In European EMQN and Chinese PQCC quality control programs, AmoyDx is the NO.1 testing kit supplier for some years and always achieves the highest accuracy rate. Nowadays AmoyDx serves an extensive domestic and international oncology network reaching over 300 hospitals in China and 50 countries all over the world. Every year hundreds of thousands of cancer patients benefit from AmoyDx products. AmoyDx is strategic diagnostics partner of AstraZeneca, Boehringer-Ingelheim, Pfizer, Merck and Illumina, providing diagnostic products and services for medicine development and clinical oncology practice.